Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

被引:40
|
作者
Durocher, Francine [1 ]
Labrie, Yvan
Soucy, Penny
Sinilnikova, Olga
Labuda, Damian
Bessette, Paul
Chiquette, Jocelyne
Laframboise, Rachel
Lepine, Jean
Lesperance, Bernard
Ouellette, Genevieve
Pichette, Roxane
Plante, Marie
Tavtigian, Sean V.
Simard, Jacques
机构
[1] Ctr Hosp Univ Quebec, Oncol & Mol Endocrinol Res Ctr, Canc Genom Lab, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Quebec City, PQ G1V 4G2, Canada
[3] Hospices Civils Lyon, Ctr Leon Berard, Unite Mixte Genet Constitutionnelle Canc Frequent, Lyon, France
[4] Hop St Justine, Ctr Cancerol Charles Bruneau, Montreal, PQ H3T 1C5, Canada
[5] Hop St Sacrement, Clin Malad Sein Deschenes Fabia, Quebec City, PQ G1S 4L8, Canada
[6] CHUQ, Serv Med Genet, Quebec City, PQ G1V 4G2, Canada
[7] Ctr Hosp Reg Rimouski, Rimouski, PQ G5L 5T1, Canada
[8] Hop Sacre Coeur, Serv Hematooncol, Montreal, PQ H4J 1C5, Canada
[9] Hop Hotel Dieu, CHUQ, Gynecol Serv, Quebec City, PQ G1R 2J6, Canada
[10] WHO, Int Agcy Res Canc, Unit Genet Canc Susceptibil, Lyon, France
[11] Univ Laval, Dept Anat & Physiol, Canada Res Chair Oncogenet, Quebec City, PQ, Canada
关键词
D O I
10.1186/1471-2407-6-230
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ataxia telangiectasia-mutated and Rad3-related (ATR) is a member of the PIK-related family which plays, along with ATM, a central role in cell-cycle regulation. ATR has been shown to phosphorylate several tumor suppressors like BRCA1, CHEK1 and TP53. ATR appears as a good candidate breast cancer susceptibility gene and the current study was designed to screen for ATR germline mutations potentially involved in breast cancer predisposition. Methods: ATR direct sequencing was performed using a fluorescent method while widely available programs were used for linkage disequilibrium (LD), haplotype analyses, and tagging SNP (tSNP) identification. Expression analyses were carried out using real-time PCR. Results: The complete sequence of all exons and flanking intronic sequences were analyzed in DNA samples from 54 individuals affected with breast cancer from non-BRCA1/2 high-risk French Canadian breast/ovarian families. Although no germline mutation has been identified in the coding region, we identified 41 sequence variants, including 16 coding variants, 3 of which are not reported in public databases. SNP haplotypes were established and tSNPs were identified in 73 healthy unrelated French Canadians, providing a valuable tool for further association studies involving the ATR gene, using large cohorts. Our analyses led to the identification of two novel alternative splice transcripts. In contrast to the transcript generated by an alternative splicing site in the intron 41, the one resulting from a deletion of 121 nucleotides in exon 33 is widely expressed, at significant but relatively low levels, in both normal and tumoral cells including normal breast and ovarian tissue. Conclusion: Although no deleterious mutations were identified in the ATR gene, the current study provides an haplotype analysis of the ATR gene polymorphisms, which allowed the identification of a set of SNPs that could be used as tSNPs for large-scale association studies. In addition, our study led to the characterization of a novel. 33 splice form, which could generate a putative truncated protein lacking several functional domains. Additional studies in large cohorts and other populations will be needed to further evaluate if common and/or rare ATR sequence variants can be associated with a modest or intermediate breast cancer risk.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Mammographic density and breast cancer in women from high-risk families.
    Pollan, Marina
    Chirivella, Isabel
    Miranda, Josefa
    Teule, Alex
    Izquierdo, Angel
    Balmana, Judith
    Beatriz Sanchez-Heras, Ana
    Llort, Gemma
    Lope, Virginia
    Hernandez, Elena
    Juan Fita, Maria Jose
    Tena, Isabel
    Robles, Luis
    Guillen-Ponce, Carmen
    Perez-Segura, Pedro
    Sol Luque-Molina, Mari
    Hernando Polo, Susana
    Blanco, Ignacio
    Brunet, Joan
    Ramon y Cajal, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel
    Yablonski-Peretz, Tamar
    Paluch-Shimon, Shani
    Gutman, Lior Soussan
    Kaplan, Yulia
    Dvir, Addie
    Barnes-Kedar, Inbal
    Kadouri, Luna
    Semenisty, Valeriya
    Efrat, Noa
    Neiman, Victoria
    Glasser, Yafit
    Michaelson-Cohen, Rachel
    Katz, Lior
    Kaufman, Bella
    Golan, Talia
    Reish, Orit
    Hubert, Ayala
    Safra, Tamar
    Yaron, Yuval
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (01) : 133 - 138
  • [43] Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel
    Tamar Yablonski-Peretz
    Shani Paluch-Shimon
    Lior Soussan Gutman
    Yulia Kaplan
    Addie Dvir
    Inbal Barnes-Kedar
    Luna Kadouri
    Valeriya Semenisty
    Noa Efrat
    Victoria Neiman
    Yafit Glasser
    Rachel Michaelson-Cohen
    Lior Katz
    Bella Kaufman
    Talia Golan
    Orit Reish
    Ayala Hubert
    Tamar Safra
    Yuval Yaron
    Eitan Friedman
    Breast Cancer Research and Treatment, 2016, 155 : 133 - 138
  • [44] Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families
    Xuan Liu
    Hans-Peter Sinn
    Hans Ulrich Ulmer
    Rodney J Scott
    Ute Hamann
    Hereditary Cancer in Clinical Practice, 2 (3)
  • [45] RAD51C germline mutations in breast and ovarian cancer cases from high -risk families
    Clague, Jessica N.
    Wilhoite, Greg
    Adamson, Aaron
    Weitzel, Jeffrey N.
    Neuhausen, Susan L.
    CANCER RESEARCH, 2011, 71
  • [46] Cancer frequency in BRCA mutation families with hereditary breast and ovarian cancer
    Cajal, Teresa Ramon y
    Capdevila, Jaume
    Carrera, Gemma
    Villanueva, Rafael
    Puig, Teresa
    Gich, Ignasi
    Diez, Orland
    Alonso, M. Carmen
    Barnadas, Agusti
    ANNALS OF ONCOLOGY, 2006, 17 : 275 - 275
  • [47] BRCA1 mutation analysis in 83 Spanish breast and breast/ovarian cancer families
    Díez, O
    Cortes, J
    Domènech, M
    Brunet, J
    Del Río, E
    Pericay, C
    Sanz, J
    Alonso, C
    Baiget, M
    INTERNATIONAL JOURNAL OF CANCER, 1999, 83 (04) : 465 - 469
  • [48] Mapping Mutations: Importance of Family Geographic Origin in Portuguese High-Risk Breast/Ovarian Cancer Families for BRCA Mutation Screening
    Fragoso, S.
    Machado, P.
    Santos, S.
    Rodrigues, P.
    Parreira, J.
    Bento, S.
    Luis, A.
    Vaz, F.
    CANCER RESEARCH, 2010, 70
  • [49] Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families
    Desjardins, Sylvie
    Belleau, Pascal
    Labrie, Yvan
    Ouellette, Genevieve
    Bessette, Paul
    Chiquette, Jocelyne
    Laframboise, Rachel
    Lepine, Jean
    Lesperance, Bernard
    Pichette, Roxane
    Plante, Marie
    Durocher, Francine
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (01) : 108 - 116
  • [50] Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer
    Wappenschmidt, Barbara
    Hauke, Jan
    Faust, Ulrike
    Niederacher, Dieter
    Wiesmueler, Lisa
    Schmidt, Gunnar
    Gross, Evi
    Gehrig, Andrea
    Sutter, Christian
    Ramser, Juliane
    Rump, Andreas
    Arnold, Norbert
    Meindl, Alfons
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (04) : 410 - 429